> For the complete documentation index, see [llms.txt](https://www.parapathology.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.parapathology.com/clippings/neuroendocrine-neoplasms-of-the-urinary-bladder-integrating-molecular-advances-into-a-refined-classi.md).

# Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System

Neuroendocrine neoplasms (NENs) of the urinary bladder are rare but highly aggressive tumors that account for under 1% of bladder malignancies. The 2022 WHO classification recognizes small cell neuroe

### Summary

A comprehensive state-of-the-art review by **Anandi Lobo** (Center for Pathology and Urology, Raipur) and **Liang Cheng** (Warren Alpert Medical School of Brown University & Lifespan Academic Medical Center) published in *Endocrine Pathology* (DOI: [10.1007/s12022-026-09932-0](https://doi.org/10.1007/s12022-026-09932-0)).

The review integrates histopathological, immunophenotypic, and genomic findings to address the fundamental shortcomings of the current **2022 WHO classification** of urinary bladder neuroendocrine neoplasms (NENs). Because the WHO framework was directly extrapolated from gastroenteropancreatic and pulmonary models, it fails to account for unique bladder-specific biology — notably the overwhelming predominance of high-grade neuroendocrine carcinomas (NECs), their common clonal origin with conventional urothelial carcinoma (UC), and the practical absence of well-differentiated high-grade tumors (NET G3).

Lobo & Cheng formulate an organ-specific, refined 4-category classification system combining mitotic rate, Ki-67 proliferation index, morphology, and molecular drivers, while outlining emerging transcriptomic lineage subgroups (ASCL1, NEUROD1, POU2F3, triple-negative) and therapeutic horizons (DLL3-targeted bispecific T-cell engagers like tarlatamab).

> The verbatim abstract is preserved in the `description:` frontmatter. The full text (23 pages, figures, tables, and 191 references) was reviewed from the version of record.

***

### Why It Matters for Clinical & Surgical Pathology

1. **Mandatory Reporting of Any Neuroendocrine Component:** In bladder cancer, finding *even minor focal* small cell or large cell neuroendocrine carcinoma (<10%) radically alters clinical care. Standard transurethral resection (TURBT) or bladder-sparing gemcitabine-cisplatin regimens are inadequate; patients require systemic **neoadjuvant chemotherapy (NAC) with platinum + etoposide (EP)** prior to radical cystectomy due to extreme propensity for early micrometastatic dissemination.
2. **Resolution of Diagnostic Traps:**
   * **TTF-1 (NKX2-1) is positive in 30–40% of primary bladder SCNECs!** Pathologists who interpret TTF-1 positivity as proof of metastasis from small-cell lung cancer (SCLC) commit a critical misdiagnosis.
   * **GATA3 is positive in 30–50% of bladder paragangliomas**, which can lead to catastrophic confusion with muscle-invasive urothelial carcinoma if cytokeratins and neuroendocrine/sustentacular markers are omitted.
3. **Anatomic Tie-Breaker via TERT Promoter Sequencing:** When patients present with synchronous lung and bladder tumors, or concurrent prostatic and bladder masses, *TERT* promoter mutation testing (*C228T* / *C250T*) serves as a definitive bladder lineage discriminator: present in **70–80%** of bladder SCNECs, but virtually absent in pulmonary SCLC and rare in prostatic small cell carcinoma.

***

### Pathogenesis: Divergent Urothelial Lineage vs. Resident Cells

Historically debated whether bladder NENs arise from resident Kultschitzky-type neuroendocrine cells, metaplastic epithelium, or stem cells. Contemporary molecular biology strongly establishes **divergent differentiation from transformed pluripotent urothelial stem cells**:

* **Frequent Co-existence:** Over 50% of bladder SCNECs and LCNECs present with concurrent non-neuroendocrine components (conventional invasive UC, high-grade urothelial carcinoma in situ \[CIS], squamous cell carcinoma, or adenocarcinoma).
* **Shared Clonal Fingerprint:** Laser-capture microdissection studies demonstrate that both components share identical loss-of-heterozygosity (LOH) patterns, identical *TP53* mutations, identical *RB1* deletions, and identical *TERT* promoter mutations.
* **Contrast with Prostatic Neuroendocrine Carcinoma:** In prostate cancer, neuroendocrine carcinoma predominantly emerges as a secondary, treatment-induced lineage plasticity switch under androgen receptor pathway inhibition (ARSI). In the bladder, SCNEC/LCNEC develops *de novo* or concurrently as part of primary clonal evolution, with no established treatment-emergent transdifferentiation paradigm following standard cytotoxic chemotherapy or immunotherapy.

***

### Molecular Architecture & Driver Alterations

```
Genomic Landscape of Bladder Poorly Differentiated NECs
├── Dual Cell Cycle Inactivation (Obligate Hallmarks)
│   ├── TP53 Inactivation: >80–90% (missense/null mutations, LOH)
│   └── RB1 Inactivation: >70–80% (deletions, truncating mutations, loss of protein)
├── Urothelial Lineage Fingerprint
│   └── TERT Promoter Mutations (C228T, C250T): 70–80% (rare in lung SCLC or prostate small cell)
├── Mutational Signatures & Epigenetics
│   ├── APOBEC Mutational Signature (APOBEC3A/3B): High TMB, hypermutation
│   └── Chromatin Remodeling: ARID1A, KDM6A, KMT2C/D (MLL), CREBBP, EP300
└── Transcriptional Repression & Cell-Surface Targets
    └── Notch Pathway Suppression → Aberrant overexpression of DLL3 (Delta-like ligand 3)
```

***

### Lobo & Cheng's Refined Bladder-Specific Classification

The authors propose a 4-tier organ-specific system tailored to bladder pathology (Table 2 in paper):

| Category                                   | Subclassification                               | Differentiation / Grade                 | Key Morphology                                                                             | Mitotic Rate (per 2.5 mm²) | Ki-67 Index      | Immunophenotype                                                                       | Molecular Features                                                    | Clinical Behaviour                     |
| ------------------------------------------ | ----------------------------------------------- | --------------------------------------- | ------------------------------------------------------------------------------------------ | -------------------------- | ---------------- | ------------------------------------------------------------------------------------- | --------------------------------------------------------------------- | -------------------------------------- |
| **Well-Differentiated NETs**               | **Bladder NET, G1**                             | Well-differentiated, Low grade          | Organoid nests, trabeculae, rosettes; bland cytology                                       | < 2                        | $\le 3%$         | Synaptophysin+, Chromogranin+, INSM1+                                                 | *TP53* & *RB1* intact                                                 | Indolent                               |
|                                            | **Bladder NET, G2**                             | Well-differentiated, Intermediate grade | As above, with mild/moderate cytologic atypia                                              | 2–20                       | 3–20%            | Synaptophysin+, Chromogranin+, INSM1+                                                 | *TP53* & *RB1* intact                                                 | Intermediate                           |
| **Poorly Differentiated NECs**             | **Small Cell Neuroendocrine Carcinoma (SCNEC)** | Poorly differentiated, High grade       | Small cells, high N:C ratio, nuclear molding, crush artifact, necrosis                     | > 20                       | Usually > 60–70% | Synaptophysin+, INSM1+; Chromogranin variable; Keratin dot-like                       | Concurrent *TP53* & *RB1* biallelic inactivation; *TERT* promoter mut | Highly aggressive                      |
|                                            | **Large Cell Neuroendocrine Carcinoma (LCNEC)** | Poorly differentiated, High grade       | Large cells, abundant cytoplasm, prominent nucleoli, organoid/trabecular nesting, necrosis | > 20                       | > 40–50%         | Synaptophysin+, Chromogranin+, INSM1+                                                 | Frequent *TP53* and *RB1* alterations; *TERT* mut                     | Highly aggressive                      |
| **Mixed Neuroendocrine Neoplasms (MiNEN)** | **Bladder MiNEN**                               | Mixed; driven by NE component           | NEC or NET admixed with UC, adenocarcinoma, or squamous cell carcinoma                     | Variable                   | Variable         | Respective markers positive in corresponding components                               | Shared clonal alterations (*TERT*, *TP53*, *RB1*)                     | Aggressive (dictated by NEC component) |
| **Paraganglioma**                          | **Bladder PGL**                                 | Well-differentiated                     | Zellballen pattern of polygonal chief cells, delicate vascular network                     | < 2                        | < 3%             | Synaptophysin+, Chromogranin+; S100/SOX10+ sustentacular; GATA3 +/-; Keratin negative | *SDHB* loss indicates germline *SDHx* syndromes                       | Indolent                               |

#### The Critical Omission: Why "NET G3" Does Not Belong in the Bladder

In the pancreas and digestive tract, NET G3 represents a well-differentiated tumor with organoid morphology, intact *TP53*/*RB1*, but elevated Ki-67 (>20%). In the urinary bladder, rigorous review of published literature and institutional series identifies **no reproducible cases of true NET G3**. Every bladder tumor exhibiting Ki-67 >20% and high mitotic activity shows the cytologic features, mutational profile (*TP53* and *RB1* co-inactivation), and aggressive clinical course of a poorly differentiated NEC (SCNEC or LCNEC). Retaining a NET G3 category in the bladder risks undertreating aggressive NECs with indolent somatostatin analogue protocols.

***

### Four Lineage Transcription Factor Subtypes in Bladder NECs

Paralleling the molecular classification of pulmonary small-cell carcinoma (SCLC-A, SCLC-N, SCLC-P, SCLC-I), bladder SCNEC and LCNEC harbor four distinct lineage subsets:

1. **ASCL1-Dominant (SCLC-A):** Classic high-neuroendocrine phenotype with robust neuroendocrine granules, high Synaptophysin/Chromogranin expression, and elevated **DLL3** levels.
2. **NEUROD1-Dominant (SCLC-N):** Intermediate neuroendocrine profile, frequent neuronal differentiation programs.
3. **POU2F3-Dominant (SCLC-P):** Tuft cell-like differentiation. Tumors are often **negative or weak for conventional neuroendocrine markers** (Synaptophysin/Chromogranin negative, but positive for POU2F3 and GFI1B). **Demonstrates significantly shorter progression-free survival (PFS) and overall survival (OS)**, representing an ultra-aggressive variant.
4. **Triple-Negative / Inflamed (SCLC-I):** Low expression of all three master transcription factors. Characterized by mesenchymal transitions, HLA upregulation, and dense immune infiltration — representing the primary candidate subset for immune checkpoint blockade.

***

### Immunohistochemical Diagnostic Workup & Traps

| Differential Diagnosis                                | Recommended IHC Panel                                                                   | Diagnostic Clues & Pitfalls                                                                                                                                                                                  |
| ----------------------------------------------------- | --------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **Primary Bladder SCNEC vs. Metastatic Lung SCLC**    | INSM1, Synaptophysin, Chromogranin, TTF-1, GATA3, CK903, *TERT* promoter NGS            | **TTF-1 is positive in 30–40% of bladder SCNECs** (cannot rule out bladder primary). *TERT* promoter mutation (*C228T/C250T*) is positive in \~80% of bladder SCNECs, negative in lung SCLC.                 |
| **Bladder SCNEC vs. Prostatic Small Cell Carcinoma**  | PSA, PSMA, NKX3.1, AR, ERG, GATA3, *TERT* promoter NGS                                  | Prostatic small cell is frequently negative for PSA/PSMA/NKX3.1 due to dedifferentiation. *TERT* promoter mutation confirms bladder urothelial lineage; prostate SCNEC lacks *TERT* mutations.               |
| **Bladder SCNEC vs. High-Grade Urothelial Carcinoma** | INSM1, Synaptophysin, GATA3, p63, RB1                                                   | High-grade UC can focally express neuroendocrine markers. **INSM1** provides crisp nuclear specificity. Complete loss of RB1 strongly supports SCNEC.                                                        |
| **Paraganglioma vs. Invasive Urothelial Carcinoma**   | Pancytokeratin (AE1/AE3, CAM5.2), GATA3, Synaptophysin, Chromogranin, S100, SOX10, SDHB | **GATA3 is positive in 30–50% of paragangliomas!** Cytokeratin is strictly negative in paraganglioma. S100/SOX10 highlights peripheral sustentacular meshwork. SDHB loss alerts for germline *SDHx* testing. |

***

### Therapeutic Horizons & The Immunotherapy Paradox

* **Neoadjuvant Platinum-Etoposide (EP):** Standard of care for muscle-invasive or high-risk bladder SCNEC prior to radical cystectomy.
* **The Immunotherapy Paradox:** Bladder SCNEC exhibits high tumor mutational burden (TMB) driven by APOBEC cytidine deaminases, yet immune checkpoint inhibitor (ICI) monotherapy has shown disappointing clinical activity. Histopathologically, the tumor microenvironment is an **"immune desert" or "immune excluded"** niche with low PD-L1 expression (0–50%), dense peritumoral extracellular matrix, and scarce intratumoral CD8+ T-cell infiltration.
* **Ineffectiveness of Bladder UC ADCs:** Enfortumab vedotin (targeting Nectin-4) and Sacituzumab govitecan (targeting TROP2) have low or absent target expression in pure SCNEC.
* **DLL3-Targeted Precision Therapy (Tarlatamab):** Downregulation of Notch signaling causes high cell-surface expression of Delta-like ligand 3 (DLL3). Following the landmark success of **tarlatamab** (bispecific T-cell engager / BiTE targeting DLL3 and CD3; demonstrated dramatic overall survival improvements in SCLC in DeLLphi-301 and Phase 3 DeLLphi-304), DLL3 represents the most promising biomarker-driven target for bladder SCNEC.